{
    "nctId": "NCT06406127",
    "briefTitle": "Effect of Alpha Lipoic Acid on Chemotherapy Induced Neurological Changes in Breast Cancer Patients",
    "officialTitle": "Effect of Alpha Lipoic Acid on Chemotherapy Induced Neurological Changes in Breast Cancer Patients",
    "overallStatus": "RECRUITING",
    "conditions": "Breast Cancer, Alpha Lipoic Acid, Paclitaxel, Neurologic Disorder, Chemotherapy",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE4",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "PREVENTION",
    "enrollmentCount": 92,
    "primaryOutcomeMeasure": "Tumor Necrotizing Factor Alpha Serum Levels",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Female breast cancer patients aged 18 to 75 years old.\n* Patients with a first diagnosis of cancer and indication for first-line therapy with Paclitaxel-based chemotherapy.\n* Patients are those who are diagnosed with Stage 1 to 3 non-metastatic breast cancer.\n* Patients are intended to receive 12 weeks of paclitaxel (75 - 80 mg/m2) according to the TC protocol.\n* No previous neurological conditions (including dementia, Alzheimer's disease, Parkinson's disease) and taking no neurological-related drugs.\n* Normal hepatic and renal function (bilirubin \u22641.5 mg/dL, creatinine \u22642.0 mg/dL).\n* Eastern Cooperative Oncology Group (ECOG) performance status from 0 - 2.\n* Patient Health Questionnaire (PHQ) score from 0 - 9.\n\nExclusion Criteria:\n\n* Hypersensitivity / Allergy to Alpha Lipoic Acid.\n* Any condition that contraindicates chemotherapy (i.e., pregnancy, lactation).\n* New-onset neurological symptoms or presence of any neurological disorder.\n* Patients with known history or current treatment with neurological agents.\n* Alcohol abuse.\n* Current participation in any other clinical investigation.",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}